Tonix Pharmaceuticals Regains Compliance with Nasdaq Least Bid Value Requirement

Tonix Pharmaceuticals Regains Compliance with Nasdaq Least Bid Value Requirement
Tonix Pharmaceuticals Regains Compliance with Nasdaq Least Bid Value Requirement

Tonix Prescribed drugs Holding Corp.

CHATHAM, N.J., June 02, 2022 (Globe NEWSWIRE) — Tonix Prescription drugs Keeping Corp. (Nasdaq: TNXP), a clinical-phase biopharmaceutical corporation, introduced right now that it has regained compliance with the least bid price tag need for ongoing listing on The Nasdaq Cash Marketplace. On June 1, 2022, Tonix acquired a letter from The Nasdaq Inventory Current market LLC stating that due to the fact Tonix’s shares had a closing bid cost at or earlier mentioned $1.00 per share for a minimal of 10 consecutive enterprise times, Tonix’s stock had regained compliance with the minimum amount bid cost requirement of $1.00 for each share for ongoing listing on The Nasdaq Money Market, as set forth in Nasdaq Listing Rule 5550(a)(2), and the matter is now shut.

About Tonix Prescribed drugs Holding Corp.1

Tonix is a clinical-stage biopharmaceutical business concentrated on discovering, licensing, obtaining and developing therapeutics to take care of and reduce human disorder and relieve struggling. Tonix’s portfolio is composed of central nervous process (CNS), scarce sickness, immunology and infectious condition item candidates. Tonix’s CNS portfolio incorporates both little molecules and biologics to address agony, neurologic, psychiatric and dependancy conditions. Tonix’s lead CNS prospect, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Period 3 growth for the management of fibromyalgia with a new Stage 3 study launched in the 2nd quarter of 2022 and interim details expected in the 1st quarter of 2023. TNX-102 SL is also becoming formulated to address Very long COVID, a serious post-acute COVID-19 problem. Tonix expects to initiate a Stage 2 review in Lengthy COVID in the second quarter of 2022. TNX-1300 (cocaine esterase) is a biologic developed to take care of cocaine intoxication that is anticipated to start out a Section 2 demo in the 2nd quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the Food and drug administration. Lastly, TNX-1900 (intranasal potentiated oxytocin), a tiny molecule in growth for persistent migraine, is predicted to enter the clinic with a Phase 2 research in the second 50 percent of 2022. Tonix’s scarce disorder portfolio consists of TNX-2900 (intranasal potentiated oxytocin) for the cure of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the Fda. Tonix’s immunology portfolio features biologics to handle organ transplant rejection, autoimmunity and most cancers, which include TNX-1500 which is a humanized monoclonal antibody concentrating on CD40-ligand remaining developed for the avoidance of allograft and xenograft rejection and for the therapy of autoimmune health conditions. A Stage 1 study of TNX-1500 is envisioned to be initiated in the second half of 2022. Tonix’s infectious disorder pipeline is composed of a vaccine in improvement to reduce smallpox and monkeypox named TNX-801, future-era vaccines to avert COVID-19, and a system to make totally human monoclonal antibodies to deal with COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-1850, which are are living virus vaccines centered on Tonix’s recombinant pox are living virus vector vaccine platform.

1All of Tonix’s item candidates are investigational new medicine or biologics and have not been accepted for any indicator.

This press launch and further more information and facts about Tonix can be discovered at

Forward On the lookout Statements

Specific statements in this press release are ahead-looking within just the that means of the Private Securities Litigation Reform Act of 1995. These statements could be determined by the use of ahead-hunting words these as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among other individuals. These ahead-on the lookout statements are based on Tonix’s existing expectations and real effects could differ materially. There are a range of things that could result in actual events to differ materially from these indicated by this sort of ahead-on the lookout statements. These factors involve, but are not restricted to, risks related to the failure to get Food and drug administration clearances or approvals and noncompliance with Fda laws delays and uncertainties brought about by the world wide COVID-19 pandemic threats linked to the timing and progress of clinical progress of our item candidates our require for added financing uncertainties of patent safety and litigation uncertainties of governing administration or third social gathering payor reimbursement limited analysis and improvement attempts and dependence on third parties and sizeable levels of competition. As with any pharmaceutical underneath improvement, there are sizeable threats in the enhancement, regulatory acceptance and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-searching assertion. Buyers should really read through the chance aspects set forth in the Yearly Report on Variety 10-K for the 12 months finished December 31, 2021, as filed with the Securities and Exchange Fee (the “SEC”) on March 14, 2022, and periodic studies filed with the SEC on or following the day thereof. All of Tonix’s forward-searching statements are expressly capable by all this kind of chance elements and other cautionary statements. The information set forth herein speaks only as of the day thereof.


Jessica Morris (corporate)
Tonix Pharmaceuticals
[email protected]
(862) 799-8599

Olipriya Das, Ph.D. (media)
Russo Companions
[email protected]
(646) 942-5588

Peter Vozzo (investors)
ICR Westwicke
[email protected]
(443) 213-0505